Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 138559 in Moderate to Severe Atopic Dermatitis (Phase 2a)
2020-005541-16Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing LEO 138559 with Placebo (2 arms). Primary endpoint: Change in EASI score from baseline to Week 16. Started Mar 2021; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-005541-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005541-16.